An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk
about
SK channels and ventricular arrhythmias in heart failureEvaluation of drug-induced QT interval prolongation in animal and human studies: a literature review of concordanceProbing the energy landscape of activation gating of the bacterial potassium channel KcsAHuman-based approaches to pharmacology and cardiology: an interdisciplinary and intersectorial workshop.Prediction of Thorough QT study results using action potential simulations based on ion channel screensEvaluation of an in silico cardiac safety assay: using ion channel screening data to predict QT interval changes in the rabbit ventricular wedge.Variability in high-throughput ion-channel screening data and consequences for cardiac safety assessment.Parameter Identifiability of Fundamental Pharmacodynamic ModelsAntidepressant-induced ubiquitination and degradation of the cardiac potassium channel hERG.Model-based evaluation of drug-induced QTc prolongation for compounds in early development.How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?Physiological, pharmacological and toxicological considerations of drug-induced structural cardiac injuryOxytocin does not directly alter cardiac repolarization in rabbit or human cardiac myocytesA new classifier-based strategy for in-silico ion-channel cardiac drug safety assessment.Role of sarcoplasmic reticulum calcium in development of secondary calcium rise and early afterdepolarizations in long QT syndrome rabbit model.Molecular determinants of pentamidine-induced hERG trafficking inhibition.Postoperative QT interval prolongation in patients undergoing noncardiac surgery under general anesthesiaA web portal for in-silico action potential predictionsSelective inhibition of Sarcocystis neurona calcium-dependent protein kinase 1 for equine protozoal myeloencephalitis therapy.Role of mixed ion channel effects in the cardiovascular safety assessment of the novel anti-MRSA fluoroquinolone JNJ-Q2Investigation of mechanism of drug-induced cardiac injury and torsades de pointes in cynomolgus monkeys.The virtual heart as a platform for screening drug cardiotoxicity.Application of cardiac electrophysiology simulations to pro-arrhythmic safety testing.Assessment of Interspecies Differences in Drug-Induced QTc Interval Prolongation in Cynomolgus Monkeys, Dogs and Humans.Computational assessment of drug-induced effects on the electrocardiogram: from ion channel to body surface potentialsApplication of a systems pharmacology model for translational prediction of hERG-mediated QTc prolongation.Reducing QT liability and proarrhythmic risk in drug discovery and development.On the relationship between block of the cardiac Na⁺ channel and drug-induced prolongation of the QRS complex.A New Perspective in the Field of Cardiac Safety Testing through the Comprehensive In Vitro Proarrhythmia Assay Paradigm.hERG subunit composition determines differential drug sensitivity.Evaluation of the Cardiotoxicity of Evodiamine In Vitro and In Vivo.5-Aminopyrazole-4-carboxamide analogues are selective inhibitors of Plasmodium falciparum microgametocyte exflagellation and potential malaria transmission blocking agents.Can silicon make an excellent drug even better? An in vitro and in vivo head-to-head comparison between loperamide and its silicon analogue sila-loperamide.From the Cover: High-Throughput Imaging of Cardiac Microtissues for the Assessment of Cardiac Contraction during Drug Discovery.Phenotypic profiling of structural cardiotoxins in vitro reveals dependency on multiple mechanisms of toxicity.Development of Safe Drugs: The hERG Challenge.Translating QT interval prolongation from conscious dogs to humans.Cardiac Non-myocyte Cells Show Enhanced Pharmacological Function Suggestive of Contractile Maturity in Stem Cell Derived Cardiomyocyte Microtissues.A Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte (hiPSC-CM) Multielectrode Array Assay for Preclinical Cardiac Electrophysiology Safety Screening.Enhanced characterization of contractility in cardiomyocytes during early drug safety assessment.
P2860
Q28083329-D2DAFCD6-52AC-4E89-AD54-077D81768293Q28083604-C953C1CC-506F-4BCB-894A-D507CF8DE09EQ28487458-C1E623C7-7AAB-4B49-BD52-8CBD6AA75AB4Q28596483-748A30A1-15A6-4364-BB4F-5C2D54CEB6C7Q28649794-DB05534F-57CD-45C9-B16C-5F2B12F28BEAQ30620268-36379810-AD98-4774-95AA-89CE61DE9FC4Q30622093-9730DEF4-3883-44C0-B53B-F3749DDD8CF7Q30830719-7DB60F97-6400-48B3-AB6F-3D150C452CCFQ33160342-E27B82EE-1C29-4B69-B2BA-4B15A6EB6860Q34953730-8963EB61-AA16-4DF3-ACEA-3902C2AB68F0Q35036150-CC0B84E4-0823-481A-A5AF-065354966EFDQ35039202-19521EE7-249A-4B1E-B85E-A11C4718ABC8Q35049595-6E110BFA-B646-4DA5-B9BF-00041CFC6962Q35211741-1377AE55-2BBB-4CE1-A7E3-D53B2E488486Q35390608-E42A96F9-C704-44D2-999F-D9F3946E86B0Q35688489-9FE8C127-1084-4147-BDCF-2220514CCC6CQ36120691-9FE934D6-0271-4CAF-BDEA-5D4119CCA753Q36120894-5651CE98-26BC-4FF8-ABA3-C773FAB72B02Q36160956-F66F001A-495B-41EE-B978-76FB02B7D3D5Q36166676-AEA26D18-7B63-4534-AC5F-68BCA37E2AA6Q36176544-AC44B99F-8335-4306-BECC-54D1D3277D60Q36342116-462366FB-ADFB-4B85-8A02-E04CFCD6EED2Q36382928-D5675AC7-6643-40F9-9FA1-3C011B7BC451Q36400366-37F50589-959D-4DE9-BDB8-E21FEFB2EFCFQ36629300-2044AEE1-E5D3-490C-9ADD-C55C44AB3386Q37579944-34F30EB3-0EC3-44F9-8BB1-150C2C027330Q37689199-99303946-354A-4876-A36F-4F3741F4BA49Q38464799-82E4CB71-C025-4568-95A6-A7F3EF044A4DQ38546437-3A9C15FB-E8B7-4F6F-86B2-627E2FCBBF93Q38649960-149C65FB-4BBA-4B81-BADB-0B0EBB464CADQ38734362-9079BD3B-DB1A-4F85-8987-7B4321008DF3Q38736811-74743343-235F-47C1-B007-A465A4C84EE0Q38896068-D45E7645-2979-4B6B-B9C5-6897CFE7A934Q39030459-EEF2DF51-77EA-44CB-86FB-D7EF72CB5CDDQ39211305-630E3BC1-15FF-40C8-A33E-D259AC368847Q39280559-D58A860F-DBC3-4077-8826-29B6CC76CC53Q39404396-4FB02565-58F9-4354-9AE2-A304AE37E873Q39812568-ED8D2282-FEC6-4B62-870D-49FB00359265Q40233317-F58D3E69-022B-4C55-9532-97EEE63D334DQ41144260-0578676B-9C0F-4378-A3F8-CF7250B0FF56
P2860
An introduction to QT interval prolongation and non-clinical approaches to assessing and reducing risk
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
An introduction to QT interval ...... to assessing and reducing risk
@en
An introduction to QT interval ...... o assessing and reducing risk.
@nl
type
label
An introduction to QT interval ...... to assessing and reducing risk
@en
An introduction to QT interval ...... o assessing and reducing risk.
@nl
prefLabel
An introduction to QT interval ...... to assessing and reducing risk
@en
An introduction to QT interval ...... o assessing and reducing risk.
@nl
P2093
P2860
P1476
An introduction to QT interval ...... to assessing and reducing risk
@en
P2093
Chris E Pollard
J-P Valentin
M H Bridgland-Taylor
N Abi Gerges
T G Hammond
P2860
P356
10.1111/J.1476-5381.2009.00207.X
P407
P577
2010-01-01T00:00:00Z